Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Qutenza for Peripheral Neuropathic Pain
2009-016457-18Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capsaicin in Peripheral neuropathic pain, postherpetic neuralgia (PHN), HIV-associated neuropathy and 2 more, sponsored by Astellas Pharma. Primary endpoint: Safety: adverse events. Started May 2010; status: completed.
02
Drugs
capsaicin
03
Conditions
Peripheral neuropathic painpostherpetic neuralgia (PHN)HIV-associated neuropathyperipheral neuropathycryptogenic small fiber neuropathy (iSFN)
Beyond the preview
Go deeper on 2009-016457-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016457-18.